271 related articles for article (PubMed ID: 25888889)
1. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study.
Kempowsky-Hamon T; Valle C; Lacroix-Triki M; Hedjazi L; Trouilh L; Lamarre S; Labourdette D; Roger L; Mhamdi L; Dalenc F; Filleron T; Favre G; François JM; Le Lann MV; Anton-Leberre V
BMC Med Genomics; 2015 Feb; 8():3. PubMed ID: 25888889
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
Sotiriou C; Wirapati P; Loi S; Harris A; Fox S; Smeds J; Nordgren H; Farmer P; Praz V; Haibe-Kains B; Desmedt C; Larsimont D; Cardoso F; Peterse H; Nuyten D; Buyse M; Van de Vijver MJ; Bergh J; Piccart M; Delorenzi M
J Natl Cancer Inst; 2006 Feb; 98(4):262-72. PubMed ID: 16478745
[TBL] [Abstract][Full Text] [Related]
3. Neural networks and Fuzzy clustering methods for assessing the efficacy of microarray based intrinsic gene signatures in breast cancer classification and the character and relations of identified subtypes.
Samarasinghe S; Chaiboonchoe A
Methods Mol Biol; 2015; 1260():285-317. PubMed ID: 25502389
[TBL] [Abstract][Full Text] [Related]
4. Genes and functions from breast cancer signatures.
Huang S; Murphy L; Xu W
BMC Cancer; 2018 Apr; 18(1):473. PubMed ID: 29699511
[TBL] [Abstract][Full Text] [Related]
5. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A
PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
7. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
Kuo WH; Chang YY; Lai LC; Tsai MH; Hsiao CK; Chang KJ; Chuang EY
PLoS One; 2012; 7(9):e45831. PubMed ID: 23049873
[TBL] [Abstract][Full Text] [Related]
8. Data mining of gene expression data by fuzzy and hybrid fuzzy methods.
Schaefer G; Nakashima T
IEEE Trans Inf Technol Biomed; 2010 Jan; 14(1):23-9. PubMed ID: 19846381
[TBL] [Abstract][Full Text] [Related]
9. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.
Chanrion M; Negre V; Fontaine H; Salvetat N; Bibeau F; Mac Grogan G; Mauriac L; Katsaros D; Molina F; Theillet C; Darbon JM
Clin Cancer Res; 2008 Mar; 14(6):1744-52. PubMed ID: 18347175
[TBL] [Abstract][Full Text] [Related]
10. Integration of RNA-Seq data with heterogeneous microarray data for breast cancer profiling.
Castillo D; Gálvez JM; Herrera LJ; Román BS; Rojas F; Rojas I
BMC Bioinformatics; 2017 Nov; 18(1):506. PubMed ID: 29157215
[TBL] [Abstract][Full Text] [Related]
11. Prediction of early breast cancer patient survival using ensembles of hypoxia signatures.
Gong IY; Fox NS; Huang V; Boutros PC
PLoS One; 2018; 13(9):e0204123. PubMed ID: 30216362
[TBL] [Abstract][Full Text] [Related]
12. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
13. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
[TBL] [Abstract][Full Text] [Related]
14. A robust fuzzy rule based integrative feature selection strategy for gene expression data in TCGA.
Fan S; Tang J; Tian Q; Wu C
BMC Med Genomics; 2019 Jan; 12(Suppl 1):14. PubMed ID: 30704464
[TBL] [Abstract][Full Text] [Related]
15. Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach.
Sun Y; Urquidi V; Goodison S
Breast Cancer Res Treat; 2010 Feb; 119(3):593-9. PubMed ID: 19291396
[TBL] [Abstract][Full Text] [Related]
16. Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?
Tonella L; Giannoccaro M; Alfieri S; Canevari S; De Cecco L
Curr Treat Options Oncol; 2017 May; 18(5):32. PubMed ID: 28474265
[TBL] [Abstract][Full Text] [Related]
17. A fuzzy gene expression-based computational approach improves breast cancer prognostication.
Haibe-Kains B; Desmedt C; Rothé F; Piccart M; Sotiriou C; Bontempi G
Genome Biol; 2010; 11(2):R18. PubMed ID: 20156340
[TBL] [Abstract][Full Text] [Related]
18. Tumor classification and marker gene prediction by feature selection and fuzzy c-means clustering using microarray data.
Wang J; Bø TH; Jonassen I; Myklebost O; Hovig E
BMC Bioinformatics; 2003 Dec; 4():60. PubMed ID: 14651757
[TBL] [Abstract][Full Text] [Related]
19. Automated Detection of Cancer Associated Genes Using a Combined Fuzzy-Rough-Set-Based F-Information and Water Swirl Algorithm of Human Gene Expression Data.
Ganesh Kumar P; Kavitha MS; Ahn BC
PLoS One; 2016; 11(12):e0167504. PubMed ID: 27936033
[TBL] [Abstract][Full Text] [Related]
20. Population-based molecular prognosis of breast cancer by transcriptional profiling.
Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
